Layoff
May 2023Announced a reduction in force; the Q1 2023 filing recognized $1.1 million of severance expense tied to the RIF and said headcount would be reduced.
SourceCompany research
Public company, workplace, funding, and market signals
Updated Jul 30, 2026
Overview
Clinical-stage biopharmaceutical company founded in 2020 in Carlsbad to discover and develop oral antivirals for viral diseases, starting with COVID-19. Its lead asset was pomotrelvir (formerly PBI-0451), but after a phase 2 miss in April 2023 the company suspended development, pursued strategic alternatives, and was acquired by MediPacific in August 2023.
Primary product
Pomotrelvir (formerly PBI-0451), an oral direct-acting antiviral for COVID-19
Founded
2020
Headquarters
Carlsbad, California, United States
Team size
51 total employees
Work style
Remote
Industry
Biotechnology
Sub-industry
Clinical-stage biopharmaceuticals / antiviral drug discovery
Open Positions
0 jobs at Pardes Biosciences
No open positions
Check back later for new openings